Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro

Despite the advancements in targeted therapy for BRAFV600E-mutated metastatic colorectal cancer (mCRC), the development of resistance to BRAFV600E inhibition limits the response rate and durability of the treatment. Better understanding of the resistance mechanisms to BRAF inhibitors will facilitate...

Descripción completa

Detalles Bibliográficos
Autores principales: Car, Iris, Dittmann, Antje, Vasieva, Olga, Bočkor, Luka, Grbčić, Petra, Piteša, Nikolina, Klobučar, Marko, Kraljević Pavelić, Sandra, Sedić, Mirela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454476/
https://www.ncbi.nlm.nih.gov/pubmed/37629086
http://dx.doi.org/10.3390/ijms241612906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454476/
https://www.ncbi.nlm.nih.gov/pubmed/37629086
http://dx.doi.org/10.3390/ijms241612906

Ejemplares similares